May 2015 May 2015
New Product - Plegridy
Plegridy (peginterferon beta-1a (rch)) is recombinant interferon beta-1a conjugated to 20 kDa methoxy poly (ethylene glycol) using an -O-2-methylpropionaldehyde linker. Plegridy is produced by recombinant DNA technology. A definitive mechanism of action of Plegridy in multiple sclerosis is not known. However, as the biological effects of Plegridy are consistent with those of non-pegylated interferon beta-1a, the mechanism of action of Plegridy is likely to be similar. Plegridy is indicated for the treatment of relapsing forms of multiple sclerosis. It is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon. The initiation of treatment is contraindicated during pregnancy, and in patients with current severe depression and/or suicidal ideation. Plegridy is available as a prefilled pen titration pack with two pens containing either 63 or 94 micrograms of peginterferon-beta-1a and a ready to use administration pack with two prefilled syringes containing 125 micrograms of peginterferon beta-1a.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au